AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25727522 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle counselling intervention
Number of subjects: 500
Study 25727522 — intervention group
Group type: COMPARATOR
Intervention: Regular instructions (control group)
Number of subjects: 500
Study 23187726 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo administration
Number of subjects: 50
Study 21996393 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenient rate control (resting HR <110 beats/min)
Number of subjects: 614
Study 21996393 — intervention group
Group type: COMPARATOR
Intervention: Strict rate control (resting HR <80 beats/min, HR during moderate exercise <110 beats/min)
Number of subjects: 614
Study 19679277 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment targeting increased neuronal hyperexcitability
Number of subjects: 0
Study 19679277 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 17039215 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprascapular nerve block (SSNB) plus standard rehabilitation treatment (Group A)
Number of subjects: 40
Study 17039215 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation treatment alone (Group B)
Number of subjects: 40
Study 14676787 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous melphalan and autologous stem cell transplantation (HDM/SCT) as initial therapy (Arm-1)
Number of subjects: 100
Study 14676787 — intervention group
Group type: COMPARATOR
Intervention: High-dose intravenous melphalan and autologous stem cell transplantation (HDM/SCT) following two cycles of oral melphalan and prednisone (Arm-2)
Number of subjects: 100
Study 11303137 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral fluconazole 400 mg per day
Number of subjects: 260
Study 11303137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study 9283994 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal silicic acid gel, orally and topically, 30 ml daily for 3 months
Number of subjects: 30
Study 9283994 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel, orally and topically, identical treatment as the intervention group
Number of subjects: 30
Study 7687592 — intervention group
Group type: EXPERIMENTAL
Intervention: Active medication 1
Number of subjects: 72
Study 7687592 — intervention group
Group type: EXPERIMENTAL
Intervention: Active medication 2
Number of subjects: 72
Study 7687592 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 3752487 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone (3 mg/kg)
Number of subjects: 0
Study 3752487 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone (6 mg/kg)
Number of subjects: 0
Study 3752487 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexitone (1 mg/kg)
Number of subjects: 0
Study 3752487 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexitone (2 mg/kg)
Number of subjects: 0
Study 3752487 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 0
Study 29336718 — intervention group
Group type: EXPERIMENTAL
Intervention: Irvingia gabonensis (150 mg) twice a day for 90 days
Number of subjects: 24
Study 29336718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 27679518 — intervention group
Group type: EXPERIMENTAL
Intervention: Patiromer 25.2 g/d
Number of subjects: 0
Study 27679518 — intervention group
Group type: EXPERIMENTAL
Intervention: Patiromer (dosing regimen study)
Number of subjects: 0
Study 25031328 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-improved amaranth sauce
Number of subjects: 18
Study 25031328 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-improved jute sauce
Number of subjects: 18
Study 25031328 — intervention group
Group type: COMPARATOR
Intervention: Traditional amaranth sauce
Number of subjects: 18
Study 22375895 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay Pregnancy Outreach Worker (POW) service
Number of subjects: 1316
Study 22375895 — intervention group
Group type: COMPARATOR
Intervention: Standard maternity care
Number of subjects: 1316
Study 20331895 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid antigen detection testing (RADT) for GABHS in acute pharyngitis
Number of subjects: 276
Study 20331895 — intervention group
Group type: COMPARATOR
Intervention: Control group (no RADT)
Number of subjects: 276
Study 20331895 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (RADT)
Number of subjects: 276
Study 17971713 — intervention group
Group type: EXPERIMENTAL
Intervention: ATV300/RTV (Atazanavir 300 mg with Ritonavir 100 mg)
Number of subjects: 0
Study 17971713 — intervention group
Group type: EXPERIMENTAL
Intervention: ATV400 (Atazanavir 400 mg)
Number of subjects: 0
Study 17971713 — intervention group
Group type: COMPARATOR
Intervention: ATV300/RTV
Number of subjects: 0
Study 17971713 — intervention group
Group type: COMPARATOR
Intervention: ATV400
Number of subjects: 0
Study 17180590 — intervention group
Group type: EXPERIMENTAL
Intervention: roxithromycin (300 mg per day)
Number of subjects: 28
Study 17180590 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 28
Study 12834498 — intervention group
Group type: EXPERIMENTAL
Intervention: GRA10
Number of subjects: 39
Study 12834498 — intervention group
Group type: COMPARATOR
Intervention: GRA1
Number of subjects: 39
Study 12834498 — intervention group
Group type: EXPERIMENTAL
Intervention: PP10
Number of subjects: 39
Study 12834498 — intervention group
Group type: COMPARATOR
Intervention: PP1
Number of subjects: 39
Study 10790931 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional assessment and counselling of mothers and carers, introduction of the Strong Women, Strong Babies, Strong Culture program
Number of subjects: 0
Study 10790931 — intervention group
Group type: COMPARATOR
Intervention: Pre-intervention conditions
Number of subjects: 0
Study 9309287 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol
Number of subjects: 16
Study 9309287 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol
Number of subjects: 16
Study 8296384 — intervention group
Group type: EXPERIMENTAL
Intervention: High-titre Edmonston-Zagreb (EZ) measles vaccine administered at 5 months
Number of subjects: 0
Study 8296384 — intervention group
Group type: EXPERIMENTAL
Intervention: High-titre Schwarz (SW-HT) measles vaccine administered at 5 months
Number of subjects: 0
Study 8296384 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Schwarz (SW-std) measles vaccine administered at 10 months
Number of subjects: 0
Study 8296384 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered at 5 months
Number of subjects: 0
Study 3443142 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg twice daily with omeprazole 20 mg
Number of subjects: 8
Study 3443142 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 80 mg twice daily with placebo
Number of subjects: 8
Study 31658396 — intervention group
Group type: EXPERIMENTAL
Intervention: HL2351 (1, 2, 4, 8 and 12 mg/kg)
Number of subjects: 0
Study 31658396 — intervention group
Group type: COMPARATOR
Intervention: Anakinra (100 mg)
Number of subjects: 0
Study 31658396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30415859 — intervention group
Group type: EXPERIMENTAL
Intervention: W0 (drinking water offered from birth)
Number of subjects: 30
Study 30415859 — intervention group
Group type: COMPARATOR
Intervention: W17 (drinking water offered at 17 d of age)
Number of subjects: 30
Study 27891663 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin (ERN)
Number of subjects: 21
Study 27891663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 25686055 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplement (Group A) - pycnogenol 50 mg, Vitamin E 30 mg, coenzyme Q10 20 mg
Number of subjects: 68
Study 25686055 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group (Group B)
Number of subjects: 68
Study 22251879 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate implant treatment (IIT)
Number of subjects: 48
Study 22251879 — intervention group
Group type: COMPARATOR
Intervention: Conventional implant treatment (CIT)
Number of subjects: 48
Study 22251879 — intervention group
Group type: EXPERIMENTAL
Intervention: Grafted implant treatment (GIT)
Number of subjects: 48
Study 21527519 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 74
Study 21527519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 18463848 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus extracorporeal therapy with PMX-B
Number of subjects: 16
Study 18463848 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 16
Study 16243418 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyamemazine (25-50 mg q.d.)
Number of subjects: 168
Study 16243418 — intervention group
Group type: COMPARATOR
Intervention: Bromazepam (3-6 mg q.d.)
Number of subjects: 168
Study 16243418 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyamemazine
Number of subjects: 168
Study 16243418 — intervention group
Group type: COMPARATOR
Intervention: Bromazepam
Number of subjects: 168
Study 16243418 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyamemazine and Bromazepam
Number of subjects: 168
Study 12795087 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus pemetrexed
Number of subjects: 456
Study 12795087 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin alone
Number of subjects: 456
Study 11103484 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 45
Study 11103484 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine-bupivacaine combination
Number of subjects: 45
Study 8925577 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic group (n=77)
Number of subjects: 558
Study 8925577 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetic group (n=481)
Number of subjects: 558
Study 1642185 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting nifedipine
Number of subjects: 39
Study 6463180 — intervention group
Group type: EXPERIMENTAL
Intervention: 65 dB SPL
Number of subjects: 12
Study 6463180 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 dB SPL
Number of subjects: 12
Study 6463180 — intervention group
Group type: EXPERIMENTAL
Intervention: 95 dB SPL
Number of subjects: 12
Study 6463180 — intervention group
Group type: EXPERIMENTAL
Intervention: 110 dB SPL
Number of subjects: 12
Study 6463180 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple reaction time task
Number of subjects: 12
Study 6463180 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive sitting task
Number of subjects: 12
Study 6463180 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual tracking task
Number of subjects: 12
Study 6463180 — intervention group
Group type: EXPERIMENTAL
Intervention: SCR amplitude
Number of subjects: 12
Study 6463180 — intervention group
Group type: EXPERIMENTAL
Intervention: P300 and other event‐related potentials
Number of subjects: 12
Study 31299751 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone morphogenetic protein (BMP)
Number of subjects: 32
Study 31299751 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF)
Number of subjects: 32
Study 31299751 — intervention group
Group type: COMPARATOR
Intervention: Control group (no BMP or PRF)
Number of subjects: 32
Study 29438271 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 μg of misoprostol
Number of subjects: 158
Study 29438271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 25801339 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading of implants (test group)
Number of subjects: 50
Study 25801339 — intervention group
Group type: COMPARATOR
Intervention: Unloaded implants for 3 months (control group)
Number of subjects: 50
Study 25801339 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants with TiUnite surface (AOX)
Number of subjects: 50
Study 25801339 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants with machine-milled surface (AM)
Number of subjects: 50
Study 25801339 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants at implant level (IL)
Number of subjects: 50
Study 25801339 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall implant survival rate
Number of subjects: 50
Study 25801339 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft tissue response
Number of subjects: 50
Study 25801339 — intervention group
Group type: EXPERIMENTAL
Intervention: Probing pocket depths
Number of subjects: 50
Study 25801339 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleeding on probing (BoP)
Number of subjects: 50
Study 25801339 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft tissue retraction
Number of subjects: 50
Study 24669986 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-enriched almond-based beverage
Number of subjects: 15
Study 24669986 — intervention group
Group type: COMPARATOR
Intervention: Placebo (almond-based beverage)
Number of subjects: 15
Study 24669986 — intervention group
Group type: EXPERIMENTAL
Intervention: Training season
Number of subjects: 15
Study 24669986 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute exercise
Number of subjects: 15
Study 22343483 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 34
Study 22343483 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-dose MPH
Number of subjects: 34
Study 22343483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 22343483 — intervention group
Group type: COMPARATOR
Intervention: Low-dose MPH
Number of subjects: 34
Study 20509332 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol (Vitamin E) 200 mg/day for 21 days
Number of subjects: 80
Study 20509332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 17719507 — intervention group
Group type: EXPERIMENTAL
Intervention: START triage protocol (scoring based on respiratory rate, pulse, and Glasgow Coma Scale)
Number of subjects: 355
Study 15196143 — intervention group
Group type: EXPERIMENTAL
Intervention: Stellate ganglion near-infrared irradiation (SGR) once weekly for 4 weeks
Number of subjects: 37
Study 15196143 — intervention group
Group type: EXPERIMENTAL
Intervention: SGR
Number of subjects: 37
Study 15196143 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 37
Study 12095056 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab (20mg day 0‐day 4) plus early cyclosporine from day 0
Number of subjects: 100
Study 12095056 — intervention group
Group type: COMPARATOR
Intervention: Thymoglobulin plus delayed cyclosporine
Number of subjects: 100
Study 9794094 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 mmol/d Mg orotate
Number of subjects: 23
Study 9794094 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 23
Study 8637449 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyrotropin (TSH)‐releasing hormone (TRH)
Number of subjects: 35
Study 8637449 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropin‐releasing hormone (GnRH)
Number of subjects: 35
Study 8637449 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovine corticotropin (ACTH)‐releasing hormone (oCRH)
Number of subjects: 35
Study 8637449 — intervention group
Group type: EXPERIMENTAL
Intervention: Human growth hormone‐(GH)‐releasing hormone (hGHRH)
Number of subjects: 35
Study 8637449 — intervention group
Group type: COMPARATOR
Intervention: N/A (Control group)
Number of subjects: 35
Study 2206032 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 102
Study 2206032 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 102
Study 2206032 — intervention group
Group type: EXPERIMENTAL
Intervention: Both agents
Number of subjects: 102
Study 7297143 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg pindolol
Number of subjects: 24
Study 7297143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 7297143 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled isoproterenol
Number of subjects: 24
Study 31631813 — intervention group
Group type: EXPERIMENTAL
Intervention: CaringGuidance™ plus usual care
Number of subjects: 100
Study 31631813 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study 28666425 — intervention group
Group type: EXPERIMENTAL
Intervention: Task shared psycho-social counselling intervention
Number of subjects: 6
Study 24943996 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster session (n = 31)
Number of subjects: 60
Study 24943996 — intervention group
Group type: EXPERIMENTAL
Intervention: Program without booster session (n = 29)
Number of subjects: 60
Study 24943996 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 60
Study 24993765 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 75
Study 24993765 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (responders)
Number of subjects: 75
Study 24993765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 22170972 — intervention group
Group type: COMPARATOR
Intervention: Standard tones
Number of subjects: 0
Study 22170972 — intervention group
Group type: EXPERIMENTAL
Intervention: Deviant tones
Number of subjects: 0
Study 20200309 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 28
Study 20200309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 17945435 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin (50 microg boluses at 22:00, 23:00, 00:00, and 01:00 h)
Number of subjects: 10
Study 17945435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 17945435 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin
Number of subjects: 10
Study 16004250 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate/perlite toothpaste
Number of subjects: 152
Study 16004250 — intervention group
Group type: COMPARATOR
Intervention: Silica control toothpaste
Number of subjects: 152
Study 12011527 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone iodine suppositories
Number of subjects: 70
Study 12011527 — intervention group
Group type: COMPARATOR
Intervention: Lactobacilli capsules
Number of subjects: 70
Study 10465068 — intervention group
Group type: EXPERIMENTAL
Intervention: rgp160 IIIB vaccine
Number of subjects: 208
Study 10465068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study 7494809 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort (30 mg)
Number of subjects: 0
Study 7494809 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone (20 mg)
Number of subjects: 0
Study 7494809 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone (25 mg)
Number of subjects: 0
Study 2185791 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (2.5 mg/h, increasing in steps of 2.5 mg/h at 2 h intervals, maximum rate 7.5 mg/h)
Number of subjects: 30
Study 2185791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 2185791 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 30
Study 677433 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 6
Study 677433 — intervention group
Group type: EXPERIMENTAL
Intervention: Levallorphan
Number of subjects: 6
Study 677433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31731005 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropifexor (TXR) 140 μg once daily
Number of subjects: 200
Study 31731005 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenicriviroc (CVC) 150 mg once daily
Number of subjects: 200
Study 31731005 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropifexor (TXR) 140 μg once daily + Cenicriviroc (CVC) 150 mg once daily
Number of subjects: 200
Study 31731005 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropifexor (TXR) 90 μg once daily + Cenicriviroc (CVC) 150 mg once daily
Number of subjects: 200
Study 31731005 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (TXR + CVC)
Number of subjects: 200
Study 31731005 — intervention group
Group type: COMPARATOR
Intervention: Monotherapies (TXR or CVC)
Number of subjects: 200
Study 31093755 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g metformin every 12 hours for five consecutive days
Number of subjects: 30
Study 31093755 — intervention group
Group type: COMPARATOR
Intervention: Usual management only
Number of subjects: 30
Study 27879195 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of baclofen 10 mg
Number of subjects: 22
Study 27879195 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of baclofen 10 mg
Number of subjects: 22
Study 27879195 — intervention group
Group type: COMPARATOR
Intervention: Comparison of test to reference formulation
Number of subjects: 22
Study 26032114 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 3759
Study 26032114 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3759
Study 23524695 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracortical approach
Number of subjects: 73
Study 23524695 — intervention group
Group type: COMPARATOR
Intervention: Medial approach
Number of subjects: 73
Study 21652026 — intervention group
Group type: EXPERIMENTAL
Intervention: Photographic vitreous haze grading technique using a 9-step logarithmic scale
Number of subjects: 142
Study 21652026 — intervention group
Group type: EXPERIMENTAL
Intervention: Photographic vitreous haze grading technique
Number of subjects: 142
Study 18785846 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser acupuncture (9.7 J/cm(2), 830 nm) for 10 min
Number of subjects: 45
Study 18785846 — intervention group
Group type: COMPARATOR
Intervention: Sham laser treatment
Number of subjects: 45
Study 16626571 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary PBSCs transplantation following G-CSF mobilization (300-600 microg/day for 5 days)
Number of subjects: 70
Study 16626571 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary PBSCs transplantation following G-CSF mobilization
Number of subjects: 70
Study 16626571 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (standard drug therapy and PCI)
Number of subjects: 70
Study 14709757 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 0